CXCL10 and COVID-19: Indeed, Blot and colleagues found no differences in in vitro IFNγ production at hospital admission between COVID-19 patients and patients with bacterial community-acquired pneumonia (median of 4.42 IU/mL compared to 2.64 IU/mL, p > 0.05), whilst the two groups differed by other inflammatory/anti-inflammatory cytokines (GM-CSF, CXCL10, IL-10) [36].